Recent studies of ceramide-based cancer therapies revealed that treatment of ovarian cancer cells with ceramide nanoliposomes [50] evoked MLKL-driven necroptosis independently of RIPK1/3 [20]. Here, MLKL is linked to ovarian carcinoma.